Magazine

Table: GSK's Strengths and Challenges


Lots of Cash and Products...

Sales in 2000 totaled $25.6 billion, profits reached $5.6 billion, the annual R&D budget approached $4 billion. Now, GSK is the leading supplier of antibiotics, antivirals, and respiratory drugs.

...But Weak Spots

To come up quickly in cancer and cardiovascular drugs, where the pipeline is thin, GSK is likely to acquire biotech or pharmaceutical products--or players--in the U.S., Europe, and Japan.

Data: Evaluate PLC


We Almost Lost the Nasdaq
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus